Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Next Previous
Trial Profile

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms GRIFFIN
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 01 Mar 2023 Results assessing stem cell mobilization in patients following frontline induction therapy in the MASTER and GRIFFIN examining stem cell mobilization yields, apheresis attempts, and engraftment outcomes for patients from each study, published in the Transplantation and Cellular Therapy
    • 13 Dec 2022 Results assessing the patient-reported outcomes (PROs) from GRIFFIN at the final study analysis after all pts completed 1 year of follow-up post maintenance therapy with 49.6 months of median follow-up presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results from a end-of-study final analysis by race (median follow-up, 49.6 mo), which occurred after all patients completed study therapy and 1 year of long-term follow-up, discontinued, or withdrew. presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top